Home > In process > Multiplex Biomarker Detection in Dried Plasma Spots: finding the best biomarker for remote blood collection > print

001     283182
005     20260113085701.0
024 7 _ |a 10.1002/alz70856_106925
|2 doi
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2026-00061
082 _ _ |a 610
100 1 _ |a Vávra, Jakub
|b 0
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Multiplex Biomarker Detection in Dried Plasma Spots: finding the best biomarker for remote blood collection
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1768290775_17527
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Background: Conventional blood sampling for the testing of Alzheimer's disease (AD) biomarkers depends on stringent, time-sensitive, and temperature-dependent protocols for processing, shipping, and storage. Dry plasma spots (DPS) present a simpler, more scalable alternative for the collection, storage, and transport of blood samples and may offer an alternative sampling when access to blood volume is limited. Notably, neurodegenerative biomarkers such as p-tau, NfL, and GFAP from DPS have demonstrated a strong correlation with paired plasma on other platforms. In this pilot study, we aimed to expand on these findings by exploring a broader panel of central nervous system (CNS) biomarkers using DPS, assessing their potential for reliable and accurate detection. Method: We used the NULISA™ platform to test multiplex detection of a CNS biomarker panel (127 proteins) in DPS and matched plasma, examining plasma–DPS correlations. A discovery cohort (n = 14; mean age 71.1 ± 12.8 years; 8 females [57%]) was selected from the Clinical Neurochemistry Laboratory in Mölndal, Sweden. DPS (Telimmune™ Plasma Separation Card) spiked with venous blood, were analysed with their paired EDTA plasma collected by traditional venipuncture. Pearson correlation was used to compare protein quantification across sample types. Result: We demonstrated several biomarker associations between DPS and plasma with a correlation coefficient >0.99 and p <0.0001 (Figure 1), including APOe4 (r = 0.996), IL6 (r = 0.995), and FABP3 (r = 0.994). Notably, AD-related biomarkers like p-tau181 (r=0.89), p-tau231 (r=0.86), GFAP (r=0.8), NPTX2 (r=0.92), NFL (r=0.95), SMOC1 (r=0.91), and total Tau (r=0.93) all showed strong correlations and p <0.0001. DOPA decarboxylase, relevant for LBD and atypical Parkinsonian disorders, also correlated strongly (r=0.98, p <0.0001). VGF, a biomarker of synaptic plasticity altered in AD and Major Depressive Disorder showed a strong correlation (r = 0.95, p <0.0001). Among 16 interleukins, 11 had r>0.8 (p <0.0003) and 4 had r>0.5 (p <0.05), with IL6 (r=0.995) and IL12 (r=0.994) correlating notably strong (p <0.0001). However, 25% of proteins have a weak correlation coefficient of r<0.5 with plasma. Conclusion: Our findings highlight the potential of DPS as a practical and scalable tool for multiplex biomarker detection. Further research is required to identify and validate optimal AD biomarkers in DPS-based multiplex assays.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
700 1 _ |a Traichel, Wiebke
|b 1
700 1 _ |a Benedet, Andrea
|b 2
700 1 _ |a Huber, Hanna
|0 P:(DE-2719)9003257
|b 3
|u dzne
700 1 _ |a Blennow, Kaj
|b 4
700 1 _ |a Montoliu-Gaya, Laia
|b 5
700 1 _ |a Ashton, Nicholas
|b 6
700 1 _ |a Zetterberg, Henrik
|b 7
773 _ _ |a 10.1002/alz70856_106925
|g Vol. 21, no. S2, p. e106925
|0 PERI:(DE-600)2201940-6
|n S2
|p e106925
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/283182/files/DZNE-2026-00061.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/283182/files/DZNE-2026-00061.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9003257
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 0
980 _ _ |a abstract
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21